Tina Witte

Stepping into 2026, the life sciences sector seems to be approaching with a sort of ‘confidence with guardrails’. Particularly coming out of the biggest, tone-setting event of the year, the JP Morgan Healthcare Conference. Comparatively speaking, the energy seemed more subdued, but not in a discouraging way. Progress and innovation messaging prevailed, despite the reportedly ‘slow start’ to the dealmaking there in San Francisco.

Biotech and pharma are no strangers to understanding the risks associated with innovation. In fact, their very existences are defined by feeding rich pipelines of developing new targets and thus, birthing new breeds of therapeutic classes and competitors.

It’s that time of year when school is back in session, and many families are shifting gears and reacclimating to routines after the buzz of summer vacation. The days ahead bring structure, but also a renewed sense of responsibility. Depending on their ages and stages, it’s back into the trenches of supporting, guiding, and preparing these ‘NextGens’ for what’s next. Whether it’s helping a kindergartner adjust to a new classroom or coaching a high school senior through rigorous college applicatio